Natalie Holles
Chief Executive Officer at THIRD HARMONIC BIO, INC.
Net worth: 14 M $ as of 2024-04-29
Profile
Natalie C.
Holles is currently the Chief Executive Officer & Director at Third Harmonic Bio, Inc., the Director at DOT Therapeutics-2, Inc., and the Lead Independent Director at Day One Biopharmaceuticals, Inc. Previously, she served as the President, Chief Executive Officer & Director at Astellas Gene Therapies, Inc., Independent Director at Allakos, Inc., Independent Director at Rubius Therapeutics, Inc., Principal at InterMune, Inc., Vice President-Business Development at KAI Pharmaceuticals, Inc., Senior VP-Corporate & Business Development at Hyperion Therapeutics, Inc., Executive Vice President-Corporate Development at Immune Design Corp., and Head-Business Development at Genentech, Inc. Ms. Holles received her undergraduate degree from Stanford University and her graduate degree from the University of Colorado Boulder.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
THIRD HARMONIC BIO, INC.
2.99% | 2024-05-08 | 1,218,836 ( 2.99% ) | 13 M $ | 2024-04-29 |
| 2024-03-14 | 57,310 ( 0.07% ) | 757 065 $ | 2024-04-29 |
Natalie Holles active positions
| Companies | Position | Start |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Director/Board Member | 2021-01-31 |
| THIRD HARMONIC BIO, INC. | Chief Executive Officer | 2020-07-31 |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Director/Board Member | 2021-02-16 |
Former positions of Natalie Holles
| Companies | Position | End |
|---|---|---|
| RUBIUS THERAPEUTICS | Director/Board Member | 2022-08-08 |
| ALLAKOS INC. | Director/Board Member | 2021-08-05 |
| AUDENTES THERAPEUTICS, INC. | Chief Executive Officer | 2021-02-28 |
| HYPERION THERAPEUTICS INC | Corporate Officer/Principal | 2015-04-30 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | 2013-05-31 |
Training of Natalie Holles
| Stanford University | Undergraduate Degree |
| University of Colorado Boulder | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ALLAKOS INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| THIRD HARMONIC BIO, INC. | Health Technology |
| Private companies | 8 |
|---|---|
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Natalie Holles
